ENSC - CIK 0001716947
The table below shows Ensysce Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.81M | -$7.50M | -$10.78M | -$17.89M | -$8.24M | -$1.25M |
| Capital expenditure | $123.64K | - | - | - | - | - |
| Investing cash flow | -$123.64K | - | - | $4.50K | - | $183.40M |
| Dividends paid | - | - | - | - | - | - |
Ensysce Biosciences, Inc. reported operating cash flow of -$7.81M for fiscal year 2025. That is down 4.0% from -$7.50M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$1.24M (FY 2018) to -$7.81M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | $184.78M |
| Financing cash flow | $8.74M | $9.88M | $8.76M | $8.77M | $20.31M | $1.10M |